6597-75-7

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-(Oxiranylmethoxy)-1,2-epoxypropane) is used as an intermediate in the preparation of cardioselective β-adrenergic receptor antagonists. These antagonists are important in the development of medications for the treatment of cardiovascular diseases, such as hypertension and angina.
As an intermediate, N-(4-(Oxiranylmethoxy)-1,2-epoxypropane) plays a crucial role in the synthesis of these cardioselective β-adrenergic receptor antagonists, contributing to their chemical structure and potential therapeutic effects. Its unique properties, such as the epoxypropane and oxiranylmethoxy groups, enable the formation of specific chemical bonds and interactions that are essential for the development of these medications.

Upstream product

• 103-90-2 4-acetaminophenol 
• 106-89-8 epichlorohydrin 
• 118712-54-2 glycidyl p-toluenesulfonate 
• 2623-33-8 4-acetoxyacetanilide 
• 123-30-8 4-amino-phenol 
• 1795-83-1 N-Phenylacetohydroxamic acid 
• 100-65-2 N-Phenylhydroxylamine 
• 98-95-3 nitrobenzene 

Downstream Products

• 131976-58-4 acetic acid-[4-(2-hydroxy-3-piperidino-propoxy)-anilide] 
• 63635-27-8 N-[3-(4-acetylamino-phenoxy)-2-hydroxy-propyl]-succinimide 
• 106163-09-1 4'-<3-(benzylisopropylamino)-2-hydroxypropoxy>acetanilide 
• 143285-75-0 1-<2-(4-aminophenyl)-1,1-dimethylamino>-3-(4-acetamidophenoxy)propan-2-ol 
• 129872-59-9 N-(4-{2-Hydroxy-3-[4-(4-methanesulfonylamino-phenyl)-piperazin-1-yl]-propoxy}-phenyl)-acetamide 
• 37936-65-5 (-)-Practolol 
• 54738-10-2 N-(4-{3-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-2-hydroxy-propoxy}-phenyl)-acetamide 
• 37936-66-6 (+)-Practolol 
• 68051-01-4 (2S)-3-(4-acetamidophenoxy)-1,2-epoxypropane 
• 39219-48-2 (R)-3-(4-acetamidophenoxy)-1,2-epoxypropane 
• 6673-35-4 practolol 
• 131813-58-6 N-(1,2,3,4-tetrahydronaphth1-yl)-2-hydroxy-3-(4-acetamidophenoxy)propanamine 
• 131813-57-5 N-(1,2,3,4-tetrahydronaphth-2-yl)-2-hydroxy-3-(4-acetamidophenoxy)-propanamine 

Relevant academic research and scientific papers

Substituted diaryl compound and preparation method and application thereof

The invention relates to the field of medicinal chemistry, in particular to a substituted diaryl compound (I). The preparation method comprises the following steps: medicine preparation and medical application thereof. Test results show that the substituted diaryl compound has a good inhibition effect on human lung cancer (A549), human ovarian cancer (SKOV3), human melanoma (A375) and human colon cancer (LOVO) cells. Formula (I):

Redox-Neutral Selenium-Catalysed Isomerisation of para-Hydroxamic Acids into para-Aminophenols

A selenium-catalysed para-hydroxylation of N-aryl-hydroxamic acids is reported. Mechanistically, the reaction comprises an N?O bond cleavage and consecutive selenium-induced [2,3]-rearrangement to deliver para-hydroxyaniline derivatives. The mechanism is studied through both 18O-crossover experiments as well as quantum chemical calculations. This redox-neutral transformation provides an unconventional synthetic approach to para-aminophenols.

Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics

We report the optimisation of a series of novel amide-piperidine (piperazine) derivatives using the multiple ligand approach with dopamine and serotonin receptors. Of the derivatives, compound 11 exhibited high affinity for the D2, 5-HT1A, and 5-HT2A receptors, but low affinity for the 5-HT2C and histamine H1 receptors and human ether-a-go-go-related gene (hERG) channels. In vivo, compound 11 reduced apomorphine-induced climbing, MK-801-induced hyperactivity and DOI-induced head twitching without observable catalepsy, even at the highest dose tested. In addition, it exhibited suppression in a CAR test. Furthermore, in a novel object recognition task, it displayed procognition properties. Therefore, compound 11 is a promising candidate multi-target antipsychotic.

Design, synthesis and evaluation of racemic 1-(4-hydroxyphenyl)-2-[3- (substituted phenoxy)-2-hydroxy-1-propyl]amino-1-propanol hydrochlorides as novel uterine relaxants

Novel 1-(4-hydroxyphenyl)-2-[3-(substituted phenoxy)-2-hydroxy-1-propyl] amino-1-propanol hydrochlorides were designed based on the pharmacophore for potent uterine relaxant activity and by utilizing the principles of structural hybridization. The designed molecules were synthesized as racemates by a novel route and were evaluated for uterine relaxant activity in vitro on isolated rat uterus and in vivo in pregnant rats. Their cAMP-releasing potential was studied using rat uterus tissue homogenates by the cAMP [3H] assay, and cardiac stimulant potential was evaluated on isolated guinea pig right atrium. All compounds exhibited potent uterine relaxant activity in vitro and produced a significant delay in the onset of labour in pregnant rats; their cAMP-releasing potential was slightly less, while their cardiac stimulant potential was insignificant as compared to isoxsuprine hydrochloride.

Synthesis, anorexigenic activity and QSAR of substituted aryloxypropanolamines

Substituted aryloxypropanolamines (6-20) were synthesized and evaluated for their anorexigenic activity. Among them 4-cyanoaryloxy (7), 2-methylaryloxy (9), 2-methoxyl aryloxy (10), 4-acetamidoaryloxy (15), 4-bromoaryloxy (16) and 4-ethylaminoaryloxy (20) exhibited potent anorexigenic activity. According to QSAR studies, the electronic parameter 'σ' plays an important role in describing the variance in activity. Birkhaeuser Boston 2004.

Determination of the enantiomeric purity and the configuration of β- aminoalcohols using (R)-2-fluorophenylacetic acid (AFPA) and fluorine-19 NMR: Application to β-blockers

A method has been developed for determining the enantiomeric purity and the absolute configuration of β-aminoalcohols of type ArOCH2CH(OH)CH2NHR (R = iPr, tBu). To determine enantiomeric purity, the amine function was first protected by a benzyl group, then the compound formed was esterified using the acid chloride of (R)-2-fluorophenylacetic acid (AFPA). The 19F NMR analysis of the derivative obtained revealed the presence of two distinctly separate signals (~2.5 ppm), the one for the RS-SR pair being the most deshielded. The configuration was determined directly on the aminoalcohol by using the acid. In stoichiometric conditions, when R = iPr, the amide function was obtained very preponderantly. The 19F NMR spectrum of the amide presented four distinct signals when derivatization was carried out by means of a reaction between the (±)-β-aminoalcohol and the (R)-AFPA. The extreme signals, which were over 3.5 ppm apart, did not belong to the same diastereomer. With R = tBu essentially the ester function was obtained. The first studies revealed the presence of two signals, though not as clearly separated as in the previous cases. Each experiment was simple to perform, and purification was not necessary. Mosher's acid gave unsatisfactory results in each case. (C) 2000 Elsevier Science Ltd.